

# Liang Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4344333/publications.pdf>

Version: 2024-02-01

5  
papers

87  
citations

1937685

4  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

142  
citing authors

#	ARTICLE	IF	CITATIONS
1	FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 4629-4633.	7.0	16
2	FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Clinical Cancer Research</i> , 2020, 26, 532-536.	7.0	58
3	Longitudinal model-based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 589-601.	1.9	5
4	Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1521-1532.	1.9	2
5	Model-based meta-analysis of the effects of non-selective and $\hat{\pm}$ 1-selective GABAA receptor agonists in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1209-1221.	1.9	6